...
首页> 外文期刊>Saudi journal of kidney diseases and transplantation : >Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress
【24h】

Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress

机译:接受静脉铁疗法的血液透析患者的氧化应激以及N-乙酰半胱氨酸在预防氧化应激中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

To determine the contribution of injectable iron administered to hemodialysis (HD) patients in causing oxidative stress and the beneficial effect of N-acetylcysteine (NAC) in re-ducing it, we studied in a prospective, double blinded, randomized controlled, cross over trial 14 adult HD patients who were randomized into two groups; one group received NAC in a dose of 600 mgs twice daily for 10 days prior to intravenous iron therapy and the other group received placebo. Both the groups were subjected to intravenous iron therapy, 100 mg of iron sucrose in 100 mL of normal saline given over a period of one hour. Blood samples for the markers of oxidative stress were taken before and after iron therapy. After the allowance of a week of wash out period for the effect of N-acetylcysteine we crossed over the patients to the opposite regimen. We measured the lipid peroxidation marker, malondiaaldehyde (MDA), to evaluate the oxidative stress and total anti-oxidant capacity (TAC) for the antioxidant level in addition to the highly sensitive C-reactive protein (HsCRP). Non-invasive assessment of endothelial dysfunction was measured by digital plethysmography before and after intravenous iron therapy. There was an increase of MDA (21.97 + 3.65% vs 7.06 + 3.65%) and highly sensitive C-reactive protein (HsCRP) (11.19 + 24.63% vs 13.19 + 7.7%) after iron administration both in the placebo and the NAC groups. NAC reduced the baseline acute systemic generation of oxidative stress when com-pared to placebo, which was statistically significant with MDA (12.76 + 4.4% vs 9.37 + 4.40%: P = 0.032) but not with HsCRP though there was a declining trend (2.85 + 22.75 % vs 8.93 + 5.19%: P = 0.112). Pre-treatment with NAC reduced the endothelial dysfunction when compared to placebo, but it was not statistically significant, except for reflection index (RI). We conclude that in our HD patients NAC reduced the oxidative stress before and after the administration of intravenous iron therapy in addition to the endothelial dysfunction induced by this treatment.
机译:为了确定向血液透析(HD)患者注射的铁在引起氧化应激中的作用以及N-乙酰半胱氨酸(NAC)降低其的有益作用,我们在一项前瞻性,双盲,随机对照,交叉试验中进行了研究14名成人HD患者被随机分为两组;一组在静脉铁疗法之前的10天内每天两次接受600毫克NAC的剂量,另一组接受安慰剂。两组均接受静脉铁疗法,在一小时内给予100毫克生理盐水中的100毫克蔗糖铁。在铁疗法之前和之后采集血样中的氧化应激指标。在为N-乙酰半胱氨酸的效果留出一周的冲洗时间后,我们将患者转为相反的方案。我们测量了脂质过氧化标记物丙二醛(MDA),以评估除高度敏感的C反应蛋白(HsCRP)之外的氧化应激水平和总抗氧化能力(TAC)的抗氧化剂水平。在静脉铁剂治疗之前和之后,通过数字体积描记法对内皮功能障碍进行非侵入性评估。在安慰剂组和NAC组中,铁剂给药后MDA(21.97 + 3.65%vs 7.06 + 3.65%)和高敏感性C反应蛋白(HsCRP)增加(11.19 + 24.63%vs 13.19 + 7.7%)。与安慰剂相比,NAC降低了基线急性全身性氧化应激的产生,与MDA相比在统计学上具有统计学意义(12.76 + 4.4%vs 9.37 + 4.40%:P = 0.032),但与HsCRP无关,尽管呈下降趋势(2.85) + 22.75%与8.93 + 5.19%:P = 0.112)。与安慰剂相比,NAC预处理可减少内皮功能障碍,但除反射指数(RI)外,无统计学意义。我们得出的结论是,在我们的HD患者中,NAC减轻了静脉铁剂治疗前后的氧化应激,并降低了这种治疗方法引起的内皮功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号